X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (585) 585
proto-oncogene proteins c-sis (479) 479
humans (412) 412
cells, cultured (350) 350
index medicus (323) 323
rats (317) 317
platelet-derived growth factor - pharmacology (304) 304
male (242) 242
platelet-derived growth factor (217) 217
mice (215) 215
expression (170) 170
platelet-derived growth factor - metabolism (165) 165
becaplermin (151) 151
muscle, smooth, vascular - drug effects (148) 148
phosphorylation (145) 145
proliferation (144) 144
cell proliferation - drug effects (143) 143
cell biology (139) 139
muscle, smooth, vascular - cytology (135) 135
biochemistry & molecular biology (134) 134
signal transduction (133) 133
proto-oncogene proteins c-sis - metabolism (127) 127
cell movement - drug effects (121) 121
female (116) 116
rats, sprague-dawley (116) 116
enzyme inhibitors - pharmacology (109) 109
signal transduction - drug effects (109) 109
muscle, smooth, vascular - metabolism (107) 107
growth-factor (104) 104
migration (93) 93
receptor, platelet-derived growth factor beta - metabolism (92) 92
proto-oncogene proteins c-sis - pharmacology (91) 91
cell proliferation (90) 90
platelet-derived growth factor - antagonists & inhibitors (89) 89
cell division - drug effects (85) 85
myocytes, smooth muscle - drug effects (85) 85
oncology (83) 83
pdgf (83) 83
dose-response relationship, drug (82) 82
peripheral vascular disease (77) 77
physiology (77) 77
receptors, platelet-derived growth factor - metabolism (75) 75
activation (73) 73
growth factors (73) 73
atherosclerosis (71) 71
rna, messenger - metabolism (71) 71
cell line (70) 70
in-vivo (69) 69
inhibition (68) 68
myocytes, smooth muscle - metabolism (68) 68
angiogenesis (67) 67
cells (67) 67
blotting, western (63) 63
pharmacology & pharmacy (63) 63
time factors (63) 63
phosphorylation - drug effects (62) 62
cardiac & cardiovascular systems (61) 61
proto-oncogene proteins c-sis - genetics (61) 61
imatinib mesylate (59) 59
receptor (59) 59
mice, inbred c57bl (58) 58
research (58) 58
cancer (57) 57
rats, wistar (57) 57
cell line, tumor (55) 55
disease models, animal (55) 55
hematology (55) 55
apoptosis (54) 54
gene-expression (54) 54
pyrimidines - pharmacology (54) 54
growth (53) 53
in-vitro (53) 53
proto-oncogene proteins c-sis - antagonists & inhibitors (53) 53
endothelial-cells (52) 52
gene expression (52) 52
transfection (52) 52
smooth-muscle-cells (51) 51
pdgf-bb (50) 50
platelet-derived growth factor - genetics (49) 49
dna - biosynthesis (48) 48
immunohistochemistry (48) 48
mitogen-activated protein kinases - metabolism (48) 48
protein kinase inhibitors - pharmacology (48) 48
smooth muscle (48) 48
differentiation (47) 47
piperazines - pharmacology (47) 47
platelet-derived growth factor - physiology (47) 47
medicine, research & experimental (46) 46
recombinant proteins - pharmacology (45) 45
proto-oncogene proteins c-akt - metabolism (44) 44
receptors (44) 44
adult (42) 42
analysis (42) 42
middle aged (42) 42
fibroblasts - drug effects (41) 41
fibroblasts - metabolism (41) 41
research article (41) 41
rna, messenger - genetics (41) 41
signal transduction - physiology (41) 41
signal-transduction (41) 41
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biochemical Pharmacology, ISSN 0006-2952, 02/2016, Volume 101, pp. 54 - 70
Pioglitazone (PIO), a PPARγ agonist that improves glycemic control in type 2 diabetes through its insulin-sensitizing action, has been shown to exhibit... 
AMPK | p70S6K | Pioglitazone | Vascular smooth muscle cells | ERK | ACTIVATED PROTEIN-KINASE | RECEPTOR-GAMMA | ANGIOTENSIN-II | NEOINTIMA FORMATION | ANTIDIABETIC DRUGS | AMERICAN-DIABETES-ASSOCIATION | INTIMAL HYPERPLASIA | INSULIN-RESISTANCE | HEART-ASSOCIATION | IN-VIVO | PHARMACOLOGY & PHARMACY | AMP-Activated Protein Kinases - metabolism | Muscle, Smooth, Vascular - metabolism | TOR Serine-Threonine Kinases - metabolism | Humans | Aorta - metabolism | PPAR gamma - metabolism | Platelet-Derived Growth Factor - genetics | TOR Serine-Threonine Kinases - antagonists & inhibitors | Protein Processing, Post-Translational - drug effects | RNA Interference | Phosphorylation - drug effects | Thiazolidinediones - pharmacology | Muscle, Smooth, Vascular - drug effects | PPAR gamma - genetics | Recombinant Proteins - metabolism | Proto-Oncogene Proteins c-sis - agonists | Proto-Oncogene Proteins c-sis - genetics | Proto-Oncogene Proteins c-sis - metabolism | Ribosomal Protein S6 Kinases, 70-kDa - metabolism | Ribosomal Protein S6 Kinases, 70-kDa - antagonists & inhibitors | AMP-Activated Protein Kinases - antagonists & inhibitors | Aorta - drug effects | Mitogen-Activated Protein Kinase 1 - antagonists & inhibitors | Cells, Cultured | Gene Silencing | Recombinant Proteins - chemistry | Enzyme Activation - drug effects | Muscle, Smooth, Vascular - cytology | AMP-Activated Protein Kinases - chemistry | Hypoglycemic Agents - pharmacology | Platelet-Derived Growth Factor - metabolism | MAP Kinase Signaling System - drug effects | PPAR gamma - antagonists & inhibitors | Signal Transduction - drug effects | PPAR gamma - agonists | Cell Proliferation - drug effects | Aorta - cytology | Platelet-Derived Growth Factor - antagonists & inhibitors | AMP-Activated Protein Kinases - genetics | Acetyl-CoA Carboxylase - metabolism | Mitogen-Activated Protein Kinase 1 - metabolism | Proto-Oncogene Proteins c-sis - antagonists & inhibitors | pioglitazone | vascular smooth muscle cells
Journal Article
Journal Article
Angiogenesis, ISSN 0969-6970, 7/2014, Volume 17, Issue 3, pp. 553 - 562
Hypoxia-inducible factor-1 (HIF-1) plays an important role in retinal and subretinal neovascularization (NV). Increased levels of HIF-1 cause increased... 
Diabetic retinopathy | HIF-1 | Biomedicine | DARPin | Age-related macular degeneration | Cancer Research | Oncology | Ophthalmology | Cardiology | Biomedicine general | Cell Biology | DARPINS | MODEL | CHOROIDAL NEOVASCULARIZATION | RETINOPATHY | PERIPHERAL VASCULAR DISEASE | MICE | PROTEINS | PROMOTER | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | NIH 3T3 Cells | Retinal Detachment - pathology | Recombinant Fusion Proteins - pharmacology | Recombinant Fusion Proteins - therapeutic use | Vascular Endothelial Growth Factor A - metabolism | Retinal Detachment - drug therapy | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Choroidal Neovascularization - drug therapy | Choroidal Neovascularization - pathology | Ischemia - complications | Protein Binding - drug effects | Receptors, LDL - deficiency | Ischemia - pathology | Recombinant Fusion Proteins - administration & dosage | Proto-Oncogene Proteins c-sis - metabolism | Mice, Inbred C57BL | Rats | Receptors, LDL - metabolism | Mice, Transgenic | Animals | Opsins - metabolism | Mice | Retinal Detachment - prevention & control | Retinal Neovascularization - drug therapy | Injections, Intraocular | Retinal Neovascularization - pathology | Proto-Oncogene Proteins c-sis - antagonists & inhibitors | Physiological aspects | Platelet-derived growth factor | Research | Neovascularization | Vascular endothelial growth factor | Genes
Journal Article
NATURE COMMUNICATIONS, ISSN 2041-1723, 07/2013, Volume 4, Issue 2129, p. 2129
Anti-platelet-derived growth factor (PDGF) drugs are routinely used in front-line therapy for the treatment of various cancers, but the molecular mechanism... 
PROTEASE-ACTIVATED LIGAND | THERAPY | ANGIOGENESIS | VEGF | MULTIDISCIPLINARY SCIENCES | LYMPHANGIOGENESIS | GROWTH-FACTOR | BEARING MICE | CANCER | LYMPHATIC METASTASIS | ADIPOSE-TISSUE | Fibrosarcoma - blood supply | Lung Neoplasms - drug therapy | Pericytes - drug effects | Humans | Carcinoma, Lewis Lung - immunology | Gene Expression Regulation, Neoplastic | Fibrosarcoma - immunology | Gene Expression Profiling | Carcinoma, Lewis Lung - blood supply | Neovascularization, Pathologic - pathology | Neoplasm Metastasis | Pericytes - pathology | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Neovascularization, Pathologic - immunology | Lung Neoplasms - blood supply | Lung Neoplasms - genetics | Proto-Oncogene Proteins c-sis - genetics | Signal Transduction | Antibodies, Monoclonal - pharmacology | Neovascularization, Pathologic - chemically induced | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Integrin alpha1beta1 - genetics | Carcinoma, Lewis Lung - drug therapy | Xenograft Model Antitumor Assays | Proto-Oncogene Proteins c-sis - immunology | Fibrosarcoma - genetics | Lung Neoplasms - immunology | Pericytes - immunology | Animals | Carcinoma, Lewis Lung - genetics | Integrin alpha1beta1 - immunology | Neovascularization, Pathologic - genetics | Cell Proliferation - drug effects | Mice | Fibrosarcoma - drug therapy | Cell Movement | Proto-Oncogene Proteins c-sis - antagonists & inhibitors | Teknik och teknologier | TEKNIKVETENSKAP | Engineering and Technology | TECHNOLOGY
Journal Article
Journal Article
Toxicology and Applied Pharmacology, ISSN 0041-008X, 01/2014, Volume 274, Issue 2, pp. 328 - 338
Induction of fibrosis during prolonged culture of precision-cut liver slices (PCLS) was reported. In this study, the use of rat PCLS was investigated to... 
Early onset of fibrosis | Precision-cut liver slices | Antifibrotic drugs | Liver fibrosis | Ex vivo model | ROSMARINIC ACID | ANGIOTENSIN-II | ANTI-FIBROTIC DRUGS | IN-VITRO | INHIBITS ACTIVATION | HEPATIC STELLATE CELLS | PHARMACOLOGY & PHARMACY | ENDOPLASMIC-RETICULUM | DERMAL FIBROBLASTS | TOXICOLOGY | GROWTH-FACTOR | IMATINIB MESYLATE | Niacinamide - analogs & derivatives | Rats, Wistar | Transforming Growth Factor beta1 - antagonists & inhibitors | Transforming Growth Factor beta1 - metabolism | Male | Valproic Acid - pharmacology | Depsides - pharmacology | Perindopril - pharmacology | Collagen Type I - genetics | Liver - drug effects | Benzamides - pharmacology | Benzylisoquinolines - pharmacology | Organ Culture Techniques | Liver Cirrhosis - drug therapy | Gene Expression | Collagen Type I - metabolism | Proto-Oncogene Proteins c-sis - genetics | Proto-Oncogene Proteins c-sis - metabolism | Down-Regulation | Liver - metabolism | Rats | Transforming Growth Factor beta1 - genetics | Pyrimidines - pharmacology | Cinnamates - pharmacology | HSP47 Heat-Shock Proteins - genetics | Imatinib Mesylate | Piperazines - pharmacology | Animals | Models, Biological | HSP47 Heat-Shock Proteins - metabolism | Connective Tissue Growth Factor - genetics | Phenylurea Compounds - pharmacology | Niacinamide - pharmacology | Connective Tissue Growth Factor - metabolism | Pyridones - pharmacology | Proto-Oncogene Proteins c-sis - antagonists & inhibitors | Drugs | Liver diseases | Analysis | Liver | Fibrosis | Gene expression | Growth factors | Index Medicus | FIBROSIS | DRUGS | GENES | LIVER | RATS | 60 APPLIED LIFE SCIENCES | ATP
Journal Article
American Journal of Pathology, The, ISSN 0002-9440, 2011, Volume 178, Issue 6, pp. 2897 - 2909
Journal Article
Journal Article
Journal Article
Biochemistry, ISSN 0006-2960, 03/2015, Volume 54, Issue 10, pp. 1918 - 1929
Journal Article
Circulation Research, ISSN 0009-7330, 04/2012, Volume 110, Issue 9, pp. 1179 - 1191
RATIONALE:A hallmark of the vascular remodeling process underlying pulmonary hypertension (PH) is the aberrant proliferation and migration of pulmonary... 
Mast cells | Pulmonary arterial hypertension | Protease-activated receptor-2 | FACTOR XA | CARDIAC & CARDIOVASCULAR SYSTEMS | RATS | mast cells | SMOOTH-MUSCLE CELL | MITOGEN | CHRONIC HYPOXIA | INFLAMMATION | ARTERIAL-HYPERTENSION | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | pulmonary arterial hypertension | EXPRESSION | MAST-CELL TRYPTASE | protease-activated receptor-2 | Cell Proliferation | Humans | Middle Aged | Monocrotaline | Male | Hypertension, Pulmonary - therapy | Young Adult | Pulmonary Artery - metabolism | RNA Interference | Time Factors | Hypoxia-Inducible Factor 1, alpha Subunit - metabolism | Myocytes, Smooth Muscle - drug effects | Disease Models, Animal | Muscle, Smooth, Vascular - drug effects | Receptor, PAR-2 - genetics | Receptor, Platelet-Derived Growth Factor beta - metabolism | Signal Transduction | Hypoxia-Inducible Factor 1, alpha Subunit - genetics | Rats | Familial Primary Pulmonary Hypertension | Hypoxia - complications | Pulmonary Artery - drug effects | Pyrimidines - pharmacology | Piperazines - pharmacology | Rats, Sprague-Dawley | Mice, Knockout | Adolescent | Ligands | Mice | Oligopeptides - pharmacology | Hypertension, Pulmonary - etiology | Cell Movement | Tryptases - metabolism | Muscle, Smooth, Vascular - metabolism | Receptor, PAR-2 - metabolism | Myocytes, Smooth Muscle - pathology | Receptor, PAR-2 - deficiency | Receptor, PAR-2 - antagonists & inhibitors | Receptor, Platelet-Derived Growth Factor beta - antagonists & inhibitors | Transfection | Adult | Female | Myocytes, Smooth Muscle - metabolism | Proto-Oncogene Proteins c-sis - metabolism | Mice, Inbred C57BL | Cells, Cultured | Antibodies, Neutralizing - pharmacology | Hypertension, Pulmonary - genetics | Hypertension, Pulmonary - metabolism | Imatinib Mesylate | Proto-Oncogene Proteins c-sis - immunology | Muscle, Smooth, Vascular - pathology | Animals | Benzamides | Hypertension, Pulmonary - pathology | Pulmonary Artery - pathology | Proto-Oncogene Proteins c-sis - antagonists & inhibitors
Journal Article
Journal Article
Oncotarget, ISSN 1949-2553, 2015, Volume 6, Issue 11, pp. 9517 - 9530
Journal Article
Transplantation, ISSN 0041-1337, 01/2016, Volume 100, Issue 1, pp. 103 - 110
BACKGROUNDExpression of both platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) is increased during the development of chronic... 
SURGERY | EFFICACY | VEGF | INDUCTION | IMMUNOLOGY | NEPHROPATHY | SU11248 | BETA-RECEPTOR | TRANSPLANTATION | ACUTE REJECTION | IMPACT | TYROSINE KINASE INHIBITOR | LIGAND | Vascular Endothelial Growth Factor B - antagonists & inhibitors | Kidney - pathology | Rats, Wistar | Vascular Endothelial Growth Factors - antagonists & inhibitors | Kidney - enzymology | Kidney - immunology | Myocytes, Smooth Muscle - pathology | Male | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Indoles - administration & dosage | Dose-Response Relationship, Drug | Allografts | Neointima | Time Factors | Pyrroles - administration & dosage | Myocytes, Smooth Muscle - drug effects | Graft Rejection - pathology | Kidney - physiopathology | Disease Models, Animal | Muscle, Smooth, Vascular - drug effects | Graft Rejection - enzymology | Kidney - drug effects | Proto-Oncogene Proteins c-sis - metabolism | Administration, Oral | Myocytes, Smooth Muscle - enzymology | Graft Rejection - physiopathology | Graft Rejection - prevention & control | Cells, Cultured | Cell Movement - drug effects | Protein Kinase Inhibitors - administration & dosage | Muscle, Smooth, Vascular - pathology | Platelet-Derived Growth Factor - metabolism | Animals | Signal Transduction - drug effects | Vascular Endothelial Growth Factor B - metabolism | Vascular Endothelial Growth Factors - metabolism | Cell Proliferation - drug effects | Graft Rejection - immunology | Chronic Disease | Muscle, Smooth, Vascular - enzymology | Platelet-Derived Growth Factor - antagonists & inhibitors | Kidney Transplantation - adverse effects | Proto-Oncogene Proteins c-sis - antagonists & inhibitors
Journal Article